Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in lab studies, though long-term safety in humans remains unknown.

Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune | Cancer ...

Researchers have identified a specific hormone produced by pancreatic beta cells as a direct driver of obesity-linked pancreatic cancer in mouse models, shifting scientific attention away from insulin ...

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

In a study published in NEJM Catalyst, Mayo Clinic researchers have demonstrated that chemotherapy can be safely delivered in ...

UPMC Hillman Cancer Center is exploring everything radiation treatment can treat, and the success has been life-changing for people.

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...